Safety, Pharmacokinetics, and Pharmacodynamics of Etavopivat (FT‐4202), an Allosteric Activator of Pyruvate Kinase‐R, in Healthy Adults: A Randomized, Placebo‐Controlled, Double‐Blind, First‐in‐Human Phase 1 Trial

• Published in: Clinical pharmacology in drug development Vol. 11; no. 5; pp. 654 - 665
• Main Authors: Forsyth, Sanjeev, Schroeder, Patricia, Geib, James, Vrishabhendra, Leela, Konstantinidis, Diamantis G., LaSalvia, Kari, Ribadeneira, Maria D., Wu, Eric, Kelly, Patrick, Kalfa, Theodosia A.
• Format: Journal Article
• Language: English
• Published: United States Wiley Subscription Services, Inc 01.05.2022; John Wiley and Sons Inc
• Subjects: Adult; Anemia, Sickle Cell; clinical trial; Dose-Response Relationship, Drug; Double-Blind Method; Double-blind studies; etavopivat; first‐in‐human study; Hemoglobin; Hemoglobins; Humans; Original; Pharmacodynamics; Pharmacokinetics; Pyruvate Kinase; safety; Sickle cell disease; clinical trial; first-in-human study; pharmacodynamics; safety; etavopivat; pharmacokinetics; sickle cell disease

Etavopivat (FT‐4202) is an orally administered, small‐molecule allosteric activator of erythrocyte pyruvate kinase‐R (PKR) in clinical development for the treatment of sickle cell disease and other hemoglobin disorders. This randomized, placebo‐controlled, double‐blind, first‐in‐human combination si...